Atlas Trials

A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

Clinical trial NCT06243198 · COMPLETED

Trial details

NCT number
NCT06243198
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2024-03-28
Primary completion
2024-09-03
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.